Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
PT Pyridam Farma Tbk
PYFA
Sector: Healthcare
Industry: Pharmaceuticals
Sub Sector: Pharmaceuticals & Health Care Research
Sub Industry: Pharmaceuticals
Live quote
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
-32
ROE
-52,11%
ROA
-4,82%
Book Value
61
Net Income
-178,28 M
Total Sales
1,62 T
Total Assets
7,39 T
DER
9.49x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
24,76%
REJUVE GLOBAL INVESTMENT PTE LTD 🔗
64,02%
Private Equity · Asing
PT. ASURANSI JIWA STARINVESTAMA 🔗
5,93%
Insurance · Lokal
DBS BANK LTD. 🔗
3,19%
Private Bank · Asing
PT ALDIRACITA SEKURITAS INDONESIA 🔗
2,10%
Securities Company · Lokal
Tentang Perusahaan
PT. Pyridam Farma Tbk. Founded in Jakarta based on Limited Company Act on November 27th 1976 and start the commercial operation since 1978 which conduct in pharmaceutical business.On its first establishmnent, the corporate produce & distribute medicine products for livestock & pet.. Since 1985 the corporate develop pharmacy division which emphasize produce and distribute health product for human and for livestock held by veterinary division.
Produk & Lini Bisnis
Currently, the Company's activities are engaged in the production and development of pharmaceutical products and trading of medical equipment as well.
Dewan Direksi
LY
Lee Yan Gwan
President Director
DW
dr. (Paulus ) Widjanarko Brotosaputro
Director
YG
Yenfrino Gunadi
Director
BS
Bedjo Stefanus
Director
Dewan Komisaris
RY
Robby Yulianto
President Commissioner
MS
Muhammad Syamsul Arifin
Independent Commissioner
ML
Maura Linda Sitanggang
Independent Commissioner
CD
Charles D. Marpaung
Independent Commissioner
Anak Usaha & Afiliasi
NamaDomisili%
 %
Trend Keuangan (5 periode terakhir) — hover bar untuk detail
Total Sales Net Income (+) Net Income (-)
2,8M 2,1M 1,4M 690jt 0 Sales 2025Q2: Rp 1.385.403.400 Net Income 2025Q2: Rp -213.201.773 2025Q2 Sales 2025Q3: Rp 2.060.241.443 Net Income 2025Q3: Rp -365.816.023 2025Q3 Sales 2025Q4: Rp 2.760.422.051 Net Income 2025Q4: Rp -379.670.100 2025Q4 Sales 2026Q1: Rp 766.533.599 Net Income 2026Q1: Rp -80.875.904 2026Q1 Sales 2026Q2: Rp 1.617.523.390 Net Income 2026Q2: Rp -178.279.785 2026Q2
2025 Q2
EPS -38
ROE -49,79%
2025 Q3
EPS -43
ROE -66,55%
2025 Q4
EPS -34
ROE -49,50%
2026 Q1
EPS -29
ROE -44,97%
2026 Q2
EPS -32
ROE -52,11%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
PeriodeTotal SalesNet IncomeTotal AssetsTotal EquityEPSROEDER
2026 Q2 1,62 T -178,28 M 7,39 T 684,19 M -32 -52,11% 9.49x
2026 Q1 766,53 M -80,88 M 7,07 T 719,41 M -29 -44,97% 8.52x
2025 Q4 2,76 T -379,67 M 6,77 T 766,99 M -34 -49,50% 7.54x
2025 Q3 2,06 T -365,82 M 6,92 T 732,88 M -43 -66,55% 8.44x
2025 Q2 1,39 T -213,20 M 6,85 T 856,40 M -38 -49,79% 7.00x
Trend Harga Penutupan & Book Value — hover titik untuk detail
Close Price Book Value
637 487 336 185 35 Book Value 2025Q2: Rp 76 Close 2025Q2: Rp 238 2025Q2 Book Value 2025Q3: Rp 65 Close 2025Q3: Rp 585 2025Q3 Book Value 2025Q4: Rp 68 Close 2025Q4: Rp 476 2025Q4 Book Value 2026Q1: Rp 64 Close 2026Q1: Rp 310 2026Q1 Book Value 2026Q2: Rp 61 Close 2026Q2: Rp 174 2026Q2
2025 Q2
Close 238
BV 76
ROA -6,22%
2025 Q3
Close 585
BV 65
ROA -7,05%
2025 Q4
Close 476
BV 68
ROA -5,61%
2026 Q1
Close 310
BV 64
ROA -4,58%
2026 Q2
Close 174
BV 61
ROA -4,82%
History Harga Penutupan & Book Value
TahunQrtClose Price (Rp)Book Value (Rp)ROA
2026 2 174 61 -4,82%
2026 1 310 64 -4,58%
2025 4 476 68 -5,61%
2025 3 585 65 -7,05%
2025 2 238 76 -6,22%
Data diperbarui pada: 2026-09-03 16:46:34